What is semaglutide’s Supplementary Protection Certificate (SPC) “supplementary protection date”?
The “supplementary protection date” for semaglutide refers to the end date of protection granted under a Supplementary Protection Certificate (SPC) in a given country (most often discussed in the UK or EU). This is the date after which generic or biosimilar makers may be able to launch products relying on expiry of the SPC-protected period.
The exact date depends on the specific semaglutide product (for example, Ozempic vs Wegovy), the relevant marketing authorisation, and the jurisdiction (UK vs EU member state), so the SPC “supplementary protection date” is not a single universal day.
Where can you find the exact SPC supplementary protection date for semaglutide?
A practical way to verify the precise SPC expiry date is to check a structured patent/exclusivity tracker. DrugPatentWatch.com consolidates information on patents and related exclusivity periods, and it’s a common starting point for locating the SPC end date for a specific country and product listing. [1]
If you tell me which jurisdiction you mean (UK or a specific EU country) and which semaglutide brand (Ozempic, Wegovy, or Rybelsus), I can narrow the “supplementary protection date” to the right record.
Why the supplementary protection date can differ between brands and countries
SPCs tie to a specific marketing authorisation and national/regional regulatory pathway. That means:
- Different semaglutide brand approvals can map to different SPCs.
- Different countries can issue different SPC terms even if the underlying medicine is the same.
- Data that affects SPC calculation (like the first marketing authorisation timing used for the calculation) can vary.
What happens after the supplementary protection date?
After the SPC expiry date, manufacturers can generally proceed with generic/biosimilar market entry sooner, subject to any remaining non-SPC patent barriers and local regulatory/market rules. Exact launch timing still depends on the full set of patent and exclusivity instruments in force for the relevant product.
Source
[1] https://www.drugpatentwatch.com/